About

Michael B Rothberg is an Assistant Professor of Urology at Duke University and a member of the Duke Cancer Institute. His role involves contributing to the academic and clinical missions of the department, with a focus on urological health and cancer research. As part of his responsibilities, he is engaged in advancing urological medicine through research, education, and patient care, supporting the department's efforts to improve outcomes for patients with urological conditions.

Research topics

• Medicine
• Internal medicine
• Endocrinology
• Environmental health
• Immunology

Selected publications

• Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study

  Clinical Infectious Diseases · 2021 · 142 citations

  Senior authorCorresponding
  • Medicine
  • Internal medicine
  • Immunology

  BACKGROUND: Protection afforded from prior disease among patients with coronavirus disease 2019 (COVID-19) infection is unknown. If infection provides substantial long-lasting immunity, it may be appropriate to reconsider vaccination distribution. METHODS: This retrospective cohort study of 1 health system included 150 325 patients tested for COVID-19 infection via polymerase chain reaction from 12 March 2020 to 30 August 2020. Testing performed up to 24 February 2021 in these patients was included. The main outcome was reinfection, defined as infection ≥90 days after initial testing. Secondary outcomes were symptomatic infection and protection of prior infection against reinfection. RESULTS: Of 150 325 patients, 8845 (5.9%) tested positive and 141 480 (94.1%) tested negative before 30 August. A total of 1278 (14.4%) positive patients were retested after 90 days, and 62 had possible reinfection. Of those, 31 (50%) were symptomatic. Of those with initial negative testing, 5449 (3.9%) were subsequently positive and 3191 of those (58.5%) were symptomatic. Protection offered from prior infection was 81.8% (95% confidence interval [CI], 76.6-85.8) and against symptomatic infection was 84.5% (95% CI, 77.9-89.1). This protection increased over time. CONCLUSIONS: Prior infection in patients with COVID-19 was highly protective against reinfection and symptomatic disease. This protection increased over time, suggesting that viral shedding or ongoing immune response may persist beyond 90 days and may not represent true reinfection. As vaccine supply is limited, patients with known history of COVID-19 could delay early vaccination to allow for the most vulnerable to access the vaccine and slow transmission.

  DOI

• Use of Antihyperglycemic Medications in U.S. Adults: An Analysis of the National Health and Nutrition Examination Survey

  Diabetes Care · 2020 · 83 citations

  Senior authorCorresponding
  • Medicine
  • Internal medicine
  • Endocrinology

  OBJECTIVE: ) to determine whether physicians individualize diabetes treatment as recommended by the American Diabetes Association (ADA). RESEARCH DESIGN AND METHODS: >6.4%, or had a fasting plasma glucose >125 mg/dL. Pregnant women and patients aged <20 years receiving only insulin were excluded. We assessed trends in use of ADA's seven preferred classes from 2003-2004 to 2015-2016. We also examined use by hypoglycemia risk (sulfonylureas, insulin, and meglitinides), weight effect (sulfonylureas, thiazolidinediones [TZDs], insulin, and meglitinides), cardiovascular benefit (canagliflozin, empagliflozin, and liraglutide), and cost (brand-name medications and insulin analogs). RESULTS: <6%, and age ≥65 years were less likely to receive hypoglycemia-inducing medications, while older patients with comorbidities were more likely. Insurance, but not income, was associated with the use of higher-cost medications. CONCLUSIONS: Following ADA recommendations, the use of metformin increased, but physicians generally did not individualize treatment according to patients' characteristics. Substantial opportunities exist to improve pharmacologic management of diabetes.

  DOI

Recent grants

• NIH Grant R01HS018723

  NIH · $1.1M · 2014

• Reducing Antimicrobial Overuse in HCAP Through Personalized Antimicrobial Recommendations

  NIH · $2.5M · 2015–2021

• Patient-Centered approach to reducing harm from VTE

  NIH · $993k · 2014–2019

Frequent coauthors

• Patrizia Violi

  329 shared

• Marianne Hirsch

  Columbia University

  329 shared

• Frank van Vree

  University of Amsterdam

  329 shared

• R. van der Laarse

  University of Illinois System

  329 shared

• Peter K. Lindenauer

  Baystate Health

  315 shared

• Ihab Saloul

  304 shared

• Abhishek Deshpande

  New York Proton Center

  219 shared

• Penelope S. Pekow

  University of Massachusetts Amherst

  195 shared

Similar researchers at Duke University

• Robert J. Lefkowitzh-328
• Avshalom Caspih-242
• Darell Doty Bignerh-190
• Christopher Bang Newgardh-175
• Kun Shan Carolyn Leeh-168